Skip to content
value.today
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI
$110 Mmarket cap on Sep 22, 2026-32.4% since Jan 2024
Compare
World rank
#18,388
Revenue
$2 M
For year ending December-2025
Net income
$-30 M
-1820.2% margin
SEC filing
Employees
69
As of December 31, 2025
SEC filing

Rani Therapeutics Holdings, Inc. in brief

Rani Therapeutics Holdings, Inc. is a listed company in the Biotechnology industry, based in San Jose, California, USA. It was founded in 2012. Its market value was $110 M on 22 September 2026, which makes it the 18,388th largest listed company in the world and the 3,476th largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $30 M. It employs about 69 people and Talat Imran is its chief executive. Its shares trade under the symbol RANI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Rani Therapeutics Holdings, Inc.

We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics and drugs.

Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. We have two configurations of the platform – the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO. We are also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200µL in liquid form with high bioavailability. We have tested preclinically the RaniPill HC with multiple therapeutics, including multiple different antibodies and peptides. In December 2025, we initiated a Phase 1 clinical trial with RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102), for the treatment of obesity.

From the company's annual report filed with the US SEC: read the report

Rani Therapeutics Holdings, Inc. timeline

4 events, 2012–2021
  1. 2012
  2. 🏁
    · approximate
    Founded
  3. 2021
  4. 💰
    Record revenue of $3 million
    FY2021, the highest of the 4 years on record.
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 2 August 2021; shares registered for exchange trading on 26 July 2021.

Events of Rani Therapeutics Holdings, Inc. from the company record, the company's financial years and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$88 M$177 M$265 M$353 M2023202420252026

World rank over time

▼ down 2,403 places since 2022
2022-01-07: #16098#16,09820222022-12-25: #15586#15,58620222023-07-30: #17619#17,61920232024-01-05: #18974#18,97420242026-03-08: #9319#9,31920262026-08-01: #17411#17,41120262026-09-22: #18501#18,5012026

Rank in USA: #3,377 (Jan 2022) · #3,185 (Dec 2022) · #3,539 (Jul 2023) · #3,384 (Jan 2024) · #1,801 (Mar 2026) · #3,429 (Aug 2026) · #3,489 (Sep 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
67.6×
Price / book
3.3×
Free cash flow yield
-17.1%
Net margin
-1820.2%
Operating margin
-2350.3%
Return on equity
-89.9%
Liabilities / assets
29.2%
Net debt
$-19M
Revenue growth
+58.3%
R&D / revenue
1239.3%
Revenue per employee
$24 K
Profit per employee
$-430 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue $0M, net income $-17M$0MFY20Fiscal year ending Dec 2021: revenue $3M, net income $-8M$3MFY21Fiscal year ending Dec 2022: revenue —, net income $-31M—FY22Fiscal year ending Dec 2023: revenue —, net income $-34M—FY23Fiscal year ending Dec 2024: revenue $1M, net income $-30M$1MFY24Fiscal year ending Dec 2025: revenue $2M, net income $-30M$2MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$2M+58.3%$-38M$-30M-1820.2%
Dec 2024$1M—$-53M$-30M-2914.6%
Dec 2023——$-66M$-34M—
Dec 2022——$-63M$-31M—
Dec 2021$3M+491.3%$-52M$-8M-306.3%
Dec 2020$0M—$-17M$-17M-3630.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-19M$0M$-19M$-0.45—
Dec 2024$-36M$0M$-36M$-1.05—
Dec 2023$-51M$1M$-52M$-1.33—
Dec 2022$-47M$2M$-48M$-1.28—
Dec 2021$-32M$1M$-33M$-0.43—
Dec 2020$-15M$1M$-16M——

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-9M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-7M$0MMar ’25Three months to Jun 2025: revenue —, net income $-7M—Jun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-10M—Dec ’25Three months to Mar 2026: revenue $2M, net income $-7M$2MMar ’26Three months to Jun 2026: revenue $2M, net income $-7M$2MJun ’26Three months to Sep 2026: revenue $2M, net income $-8M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Rani Therapeutics Holdings, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-38 M
Net income
$-30 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$59 M
Total liabilities
$17 M
Total equity
$33 M

As of December-2025

Top 68 institutional investors in Rani Therapeutics Holdings, Inc.#

As of Sep 30, 2026
68 institutions held 46.7 M shares (about 33.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Rani Therapeutics Holdings, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Samsara Biocapital, LLC10,369,1590 (0.00%)7.44%$8 MNov 16, 2026
2Ra Capital Management, L.P.8,500,0000 (0.00%)6.10%$7 MNov 16, 2026
3AWM Investment Company, Inc.7,500,0000 (0.00%)5.38%$6 MNov 13, 2026
4Vanguard Capital Management LLC4,566,458+3,473 (+0.08%)3.28%$4 MNov 13, 2026
5Longaeva Partners L.P.2,329,4590 (0.00%)1.67%$2 MNov 16, 2026
6Polar Asset Management Partners Inc.2,000,000-318,542 (-13.74%)1.44%$2 MNov 16, 2026
7Siren, L.L.C.1,594,800-405,200 (-20.26%)1.15%$1 MNov 12, 2026
8Gsa Capital Partners LLP1,049,321+799,605 (+320.21%)0.75%$1 MNov 16, 2026
9Millennium Management LLC968,531New0.70%$1 MNov 16, 2026
10Heights Capital Management, Inc934,5800 (0.00%)0.67%$1 MNov 16, 2026
11Geode Capital Management, LLC925,138+34,520 (+3.88%)0.66%$1 MNov 6, 2026
12Citadel Advisors LLC751,381+109,386 (+17.04%)0.54%$1 MNov 16, 2026
13Vanguard Fiduciary Trust Co547,007+88,881 (+19.40%)0.39%$0 MNov 13, 2026
14Renaissance Technologies LLC540,540+109,803 (+25.49%)0.39%$0 MNov 12, 2026
15Nan Fung Group Holdings Ltd493,5840 (0.00%)0.35%$0 MNov 13, 2026
16State Street Corp395,642+22,500 (+6.03%)0.28%$0 MNov 12, 2026
17Nano Cap New Millennium Growth Fund L P362,500New0.26%$0 MNov 13, 2026
18BlackRock, Inc.347,865+5,752 (+1.68%)0.25%$0 MNov 13, 2026
19Marshall Wace, LLP329,132-257,133 (-43.86%)0.24%$0 MNov 13, 2026
20United Services Automobile Association302,7430 (0.00%)0.22%$0 MNov 13, 2026
21Kestra Private Wealth Services, LLC290,376+8,036 (+2.85%)0.21%$0 MNov 6, 2026
22UBS Group AG230,867-66,403 (-22.34%)0.17%$0 MNov 10, 2026
23Susquehanna International Group, LLP179,167+121,377 (+210.03%)0.13%$0 MNov 16, 2026
24Northern Trust Corp170,4710 (0.00%)0.12%$0 MNov 16, 2026
25CWA Asset Management Group, LLC150,0000 (0.00%)0.11%$0 MOct 19, 2026
Show all 68: investors 26 to 68
Institutional investors 26 to 68 in Rani Therapeutics Holdings, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jane Street Group, LLC110,441-375,458 (-77.27%)0.08%$0 MNov 12, 2026
27Citigroup Inc82,900+80,257 (+3036.59%)0.06%$0 MNov 4, 2026
28King Luther Capital Management Corp58,0000 (0.00%)0.04%$0 MNov 5, 2026
29Well Done, LLC52,0140 (0.00%)0.04%$0 MOct 20, 2026
30Janney Montgomery Scott LLC49,2000 (0.00%)0.04%$0 MNov 12, 2026
31Motco48,1290 (0.00%)0.03%$0 MNov 9, 2026
32HRT Financial LP34,913New0.03%$0 MNov 13, 2026
33Squarepoint Ops LLC32,420-9,482 (-22.63%)0.02%$0 MNov 9, 2026
34Zurcher Kantonalbank (Zurich Cantonalbank)31,987+12,936 (+67.90%)0.02%$0 MNov 10, 2026
35Vanguard Global Advisers, LLC31,7510 (0.00%)0.02%$0 MNov 13, 2026
36Morgan Stanley31,156+670 (+2.20%)0.02%$0 MNov 13, 2026
37Bank Of America Corp /de/31,073New0.02%$0 MNov 16, 2026
38Lafayette Investments, Inc.22,9790 (0.00%)0.02%$0 MNov 12, 2026
39Traphagen Investment Advisors LLC22,0240 (0.00%)0.02%$0 MOct 14, 2026
40China Universal Asset Management Co., Ltd.21,061+3,174 (+17.74%)0.02%$0 MOct 28, 2026
41Farallon Capital Management, L.L.C.20,7000 (0.00%)0.01%$0 MNov 16, 2026
42Cerity Partners LLC19,0900 (0.00%)0.01%$0 MNov 13, 2026
43Goldman Sachs Group Inc17,051+5,311 (+45.24%)0.01%$0 MNov 16, 2026
44SBI Securities Co., Ltd.15,676+167 (+1.08%)0.01%$0 MOct 22, 2026
45ACT Advisors, LLC.14,701-105 (-0.71%)0.01%$0 MOct 15, 2026
46Bank of New York Mellon Corp13,8790 (0.00%)0.01%$0 MNov 5, 2026
47Farther Finance Advisors, LLC13,8000 (0.00%)0.01%$0 MOct 8, 2026
48Clear Wave Wealth Management LLC13,2280 (0.00%)0.01%$0 MNov 4, 2026
49Disciplined Investors, L.L.C.12,2000 (0.00%)0.01%$0 MNov 12, 2026
50Rockefeller Capital Management L.P.12,045+500 (+4.33%)0.01%$0 MNov 13, 2026
51Sanctuary Advisors, LLC12,0140 (0.00%)0.01%$0 MNov 13, 2026
52Prime Capital Investment Advisors, LLC11,4850 (0.00%)0.01%$0 MOct 20, 2026
53Barclays PLC10,486+450 (+4.48%)0.01%$0 MNov 6, 2026
54Tower Research Capital LLC (TRC)10,155-19,588 (-65.86%)0.01%$0 MNov 16, 2026
55Cary Street Partners Financial LLC10,000-550 (-5.21%)0.01%$0 MNov 12, 2026
56Jpmorgan Chase & Co6,284-837 (-11.75%)0.00%$0 MNov 12, 2026
57Mirae Asset Global Investments Co., Ltd.5,898+872 (+17.35%)0.00%$0 MOct 29, 2026
58Glass Jacobson Investment Advisors llc5,000New0.00%$0 MOct 26, 2026
59Osaic Holdings, Inc.4,287+500 (+13.20%)0.00%$0 MNov 12, 2026
60Group One Trading LLC4,285+561 (+15.06%)0.00%$0 MNov 10, 2026
61Simplex Trading, LLC2,912-2,224 (-43.30%)0.00%$0 MNov 4, 2026
62BNP Paribas Financial Markets1,830-304 (-14.25%)0.00%$0 MNov 12, 2026
63Jones Financial Companies Lllp1,0000 (0.00%)0.00%$0 MNov 13, 2026
64Smartleaf Asset Management LLC1,000New0.00%$0 MNov 10, 2026
65Royal Bank Of Canada140+16 (+12.90%)0.00%$0 MNov 16, 2026
66John Boyer, Inc.100New0.00%$0 MOct 27, 2026
67Northwestern Mutual Wealth Management Co50-1,050 (-95.45%)0.00%$0 MNov 13, 2026
68FMR LLC23New0.00%$0 MNov 10, 2026

Mutual funds holding Rani Therapeutics Holdings, Inc.#

10 funds hold shares worth $4 M (about 4.6% of the company). Since their previous reports 2 added shares and 7 sold, selling $0 M net.
Mutual funds holding Rani Therapeutics Holdings, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.65 M$3 M3.1%<0.01%−1.5%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.834,894$1 M0.70%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC402,359$0 M0.34%<0.01%−0.0%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC138,177$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC115,378$0 M0.10%<0.01%+3.2%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC114,500$0 M0.10%0.06%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC61,920$0 M0.05%<0.01%+25%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.49,891$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.31,501$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC479$0 M<0.01%<0.01%−1.6%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Rani Therapeutics Holdings, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$50 K
2 purchases, 2 insiders
Sold, 12 months
$301
1 sale, 1 insider
Net, 12 months
$50 K
open market only
Insiders on file
16
since
$10.7 M-$15.7 M$0Nov 2023: bought $10.7 M (6 trades), sold $10.6 M (1 trades)Nov 23Dec 2023: bought $36 K (2 trades), sold $0 (0 trades)DecOct 2024: bought $0 (0 trades), sold $10.1 M (2 trades)OctDec 2024: bought $50 K (2 trades), sold $11 K (1 trades)DecOct 2025: bought $1.3 M (1 trades), sold $15.7 M (2 trades)OctMar 2026: bought $0 (0 trades), sold $301 (1 trades)MarJul 2026: bought $50 K (2 trades), sold $0 (0 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Rani Therapeutics Holdings, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Alireza JavadiChief Technical OfficerShares withheld for tax-309$0.760$2359,071Form 4
filed Talat ImranChief Executive Officer, DirectorShares withheld for tax-7,928$0.760$6 K461,808Form 4
filed Mir A. ImranDirector, 10% ownerBuy+36,000$0.690$25 K2.12 MForm 4
filed Talat ImranChief Executive Officer, DirectorBuy+35,000$0.720$25 K469,736Form 4
filed Alireza JavadiChief Technical OfficerShares withheld for tax-309$0.740$2299,380Form 4
filed Talat ImranChief Executive Officer, DirectorShares withheld for tax-7,927$0.740$6 K434,736Form 4
filed Alireza JavadiChief Technical OfficerSell-386$0.780$3019,689Form 4
filed Talat ImranChief Executive Officer, DirectorShares withheld for tax-9,099$0.810$7 K442,663Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Rani Therapeutics Holdings, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
8.2 M
17.2 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-10-17 19:32 UTC, code LUDP, resumed 19:37 UTC
  • 2025-10-17 16:14 UTC, code LUDP, resumed 16:19 UTC
  • 2025-10-17 16:07 UTC, code LUDP, resumed 16:12 UTC
  • 2025-10-17 15:55 UTC, code LUDP, resumed 16:00 UTC
  • 2025-10-17 15:50 UTC, code LUDP, resumed 15:55 UTC

Fails to deliver

  • : 81,101 shares at $0.79
  • : 80 shares at $0.87
  • : 5 shares at $0.86
  • : 1,439 shares at $0.79
  • : 55,228 shares at $0.70

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Rani Therapeutics Holdings, Inc. scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in financial health (3 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Sep 22, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.3×Price to book 3.3× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median67.6×Price to sales 67.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-17.1%Free cash flow is -17.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 3
    • ✓Revenue grew in the newest year58.2%Revenue up 58.2% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.45 vs -1.05Diluted EPS -0.45 in fiscal 2025 against -1.05 the year before (report's currency).
    • ✗Net income higher than five years earlier-$30 M-$30 M in fiscal 2025 against -$17 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$30 MNet income -$30 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-169.5%-169.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 6
    • ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.21 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $19 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-13.3×Operating income -13.3 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-0.60Z-score -0.60 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year135.7%Diluted shares up 135.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Rani Therapeutics Holdings, Inc.'s statements, beside the median of Biotechnology.

Rani Therapeutics Holdings, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Return on equity-169.5%-61.0%
Revenue growth58.3%15.8%
Debt to equity0.00×0.26×

4of 8on the Piotroski tests of financial strength

  • Net loss of $30 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$19 million.
  • The share count rose 135.7% in the year.
  • Operating income covers the interest bill only -13.3 times.

Rani Therapeutics Holdings, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Rani Therapeutics Holdings, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue1.61.0002.70.5
Research and development202740372612
General and administrative20242627285.0
Operating expenses4054666354r−17
Operating income−38−53−66−63−52−17
Interest and finance income————0.10.1
Interest expense and finance costs2.95.05.11.10.50.1
Income before tax——−68−63−53−17
Income tax0000.10.00.0
Net income including minority interests−41−57−68−63−53−17
Minority interests' share of net income−11−27−34−33−45−17
Net income attributable to shareholders−30−30−34−31−8.3—
Earnings per share, basic-0.45-1.05-1.33-1.28-0.43—
Earnings per share, diluted-0.45-1.05-1.33-1.28-0.43—
Shares, weighted average (basic)0.10.00.00.00.0—
Shares, weighted average (diluted)0.10.00.00.00.0r—
Balance sheet
Cash and cash equivalents193.85.92711773
Short-term investments———99——
Receivables2.00————
Other current assets————2.1—
Current assets53305110112075
Property, plant and equipment0.71.56.16.04.64.5
Right-of-use (leased) assets4.35.10.71.10—
Total assets59375810812479
Accounts payable0.31.40.61.51.10.5
Debt due within a year0154.90—1.4
Current liabilities13208.04.82.65.3
Long-term debt09.6242902.4
Lease liabilities (non-current)2.73.600.10—
Total liabilities173332342.68.0
Retained earnings−133−103−73−39−8.3−114
Shareholders' equity332.0133747−113
Minority interests8.51.51337740
Total equity423.52574122−113
Total liabilities and equity59375810812479
Cash-flow statement
Depreciation and amortization0.91.00.80.50.5—
Share-based compensation12161916230
Cash from operating activities−19−35−51−47−32−15
Capital expenditure−0.1−0.3−1.2−1.6−0.5−1.2
Cash from investing activities−7.02030−72−0.5−1.2
Debt repaid−21−5.00———
Shares issued————71—
Cash from financing activities40140.2297773
Change in cash15−2.1−21−904457
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Rani Therapeutics Holdings, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling
  • Auditor changedFiling

Delisting notice 4 · Auditor changed 2 · Directors and officers 5 · Material agreement 2 · Agreement ended 1 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 9

Rani Therapeutics Holdings, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Delisting noticeDirectors and officersResults announced8-K
Results announced8-K
Agreement endedShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Auditor changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Rani Therapeutics Holdings, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$60 MPrivate placement after listing$50 to $250 million15equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Rani Therapeutics Holdings, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $126 K a year.

Certified, FY2026
2
#1,548 among companies on value.today
Worker positions
2
Median wage offered
$126 K
a year, full-time
Applications filed
2
Rani Therapeutics Holdings, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Mechanical Engineer IIIMechanical Engineers1$132 K
Validation Engineer IIValidation Engineers1$120 K

Where: San Jose, CA 2

Rani Therapeutics Holdings, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$126 K2
FY202544$120 K4
FY202444$141 K4
FY202399$120 K10
FY202244$123 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Rani Therapeutics, LLC

Layoffs at Rani Therapeutics Holdings, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2023–2023
Latest
—
2023-11-01
Rani Therapeutics Holdings, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
Rani Therapeutics Holdings, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
25% of workforceRestructuring planSEC 8-K“The Restructuring provides for a reduction of the Company’s workforce by approximately 25%.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Rani Therapeutics Holdings, Inc. compares in Biotechnology

  • Market cap$110 M · higher than 37% of 726
  • Revenue$2 M · higher than 29% of 647
  • Revenue growth58.3% · higher than 75% of 438
  • Price / sales67.6× · lower than 14% of 339
  • Price / book3.3× · lower than 44% of 534
  • FCF yield-17.1% · higher than 47% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Rani Therapeutics Holdings, Inc.🇺🇸$110 M——+58.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Sep 22, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Rani Therapeutics Holdings, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Rani Therapeutics Holdings, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Rani Therapeutics Holdings, Inc.? Suggest a correction